Nonclinical and clinical experiences with CPP-based self-assembling peptide systems in topical drug development.
Considerations in rational designs of CPP-based transcutaneous delivery systems are described. Impact of design considerations of nonclinical and clinical results are presented in detail.
Revance Therapeutics Inc, Newark, CA, USA.
Jacob M
JM
Waugh
Jane
J
Lee
Michael D
MD
Dake
Dan
D
Browne
D000279:Administration, Cutaneous; D000595:Amino Acid Sequence; D000818:Animals; D057846:Cell-Penetrating Peptides / Q000008:administration & dosage* / Q000009:adverse effects / Q000737:chemistry / Q000378:metabolism*; D002986:Clinical Trials as Topic; D004337:Drug Carriers / Q000008:administration & dosage* / Q000009:adverse effects / Q000737:chemistry / Q000378:metabolism*; D055808:Drug Discovery / Q000379:methods*; D004353:Drug Evaluation, Preclinical; D006801:Humans; D008969:Molecular Sequence Data
D057846:Cell-Penetrating Peptides; D004337:Drug Carriers